Business Context and Reporting Period
This Form 8-K was filed by Artelo Biosciences, Inc. on September 13, 2021. The report addresses two primary corporate events: a notice of non-compliance with Nasdaq listing standards regarding minimum bid price and a resolution to change the company's fiscal year end.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing status. It does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for these items.
Material Changes
- Nasdaq Non-Compliance: The Company received notice from The Nasdaq Stock Market LLC that it failed to meet the $1.00 minimum bid price requirement (Listing Rule 5550(a)(2)).
- Compliance Timeline: The Company has 180 calendar days (until March 14, 2022) to regain compliance. This requires the closing bid price to meet or exceed $1.00 for at least ten consecutive business days.
- Fiscal Year Change: The Board of Directors resolved to change the fiscal year end from August 31 to December 31. The new fiscal year begins January 1, 2022.
Outlook, Risks, and Management Commentary
- Delisting Risk: If compliance is not achieved by March 14, 2022, Nasdaq may grant a second 180-day period contingent on meeting other listing standards (e.g., market value of publicly held shares). Failure to comply within all allotted periods could result in delisting.
- Remediation Options: Management intends to monitor the stock price and may consider implementing a reverse stock split to cure the deficiency if necessary.
- Immediate Impact: The notification has no immediate effect on the listing of the common stock.
- Reporting Obligations: The Company will file a transition report to account for the fiscal year change.
Investor Verification Checklist
- Verify the current closing bid price of ARTL to assess progress toward the $1.00 threshold.
- Monitor future filings for announcements regarding a potential reverse stock split.
- Review the upcoming transition report for financial data covering the partial fiscal year ending December 31, 2021.
- Check for any subsequent Nasdaq communications regarding the extension of the compliance period.